# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-20-009201
Filing Date
2020-04-17
Accepted
2020-04-17 17:01:06
Documents
3
Period of Report
2020-05-28
Effectiveness Date
2020-04-17

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | nc10006524x1_def14a.htm | DEF 14A | 1768224
2 |  | nc10006524x1_pc1.jpg | GRAPHIC | 704543
3 |  | nc10006524x1_pc2.jpg | GRAPHIC | 646352
| Complete submission text file | 0001140361-20-009201.txt |  | 3629143

Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34207 | Film No.: 20800373
SIC: 2834 Pharmaceutical Preparations